Please login to the form below

Not currently logged in
Email:
Password:

Stivarga

This page shows the latest Stivarga news and features for those working in and with pharma, biotech and healthcare.

Home-grown colorectal cancer drug approved in China

Home-grown colorectal cancer drug approved in China

Elunate will have to go up against well-established oral drugs like Bayer’s multikinase inhibitor Stivarga (regorafenib) and Taiho Oncology’s Lonsurf (trifluridine/tipiracil) in the third-line setting.

Latest news

  • Pharma sales help Bayer escape the worst from a bumpy 2017 Pharma sales help Bayer escape the worst from a bumpy 2017

    The two brands, along with cancer drugs Xofigo and Stivarga and pulmonary hypertension treatment Adempas, are seen by the company as its key growth brands.

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Meanwhile, NICE has decided to remove Bayer’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the

  • Bayer's Nexavar backed by NICE for liver cancer Bayer's Nexavar backed by NICE for liver cancer

    Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the US for patients with HCC," said Bayer in a statement. ... Stivarga is the first and only treatment that has demonstrated a significant

  • FDA OK for Stivarga ends decade-long drought in liver cancer FDA OK for Stivarga ends decade-long drought in liver cancer

    Bayer's medicine wins US approval to treat hepatocellular carcinoma. Bayer has bagged FDA approval for Stivarga as a treatment for patients with a common form of liver cancer, becoming the ... Oral multikinase inhibitor Stivarga (regorafenib) has been

More from news
Approximately 12 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics